<p>资产管理一号有限公司在最近向证券交易委员会提交的文件中表示，在第四季度其在雅培（NYSE:ABT - 免费报告）股票中的持股增加了 8.4%。该公司在此期间额外购买了 60,871 股后，持有 781,611 股该医疗产品制造商的股票。根据其最近的 SEC 文件，资产管理一号有限公司在雅培的持股价值为 89,877,000 美元。</p>
<p>获取 <strong>雅培</strong> 的提醒：</p>
<ul>
<li>雅培将在 2025 年表现优于医疗股票</li>
</ul>
<p>其他机构投资者和对冲基金也对该公司的持仓进行了调整。Insight Folios Inc 在第三季度将其在雅培的持股增加了 3.3%。Insight Folios Inc 现在拥有 2,691 股该医疗产品制造商的股票，价值 307,000 美元，此前在上个季度额外购买了 87 股。Sfmg LLC 在第三季度将其在雅培的持股增加了 1.9%。Sfmg LLC 现在拥有 4,622 股该医疗产品制造商的股票，价值 527,000 美元，此前在此期间额外购买了 88 股。River Street Advisors LLC 在第四季度将其在雅培的持股增加了 1.2%。River Street Advisors LLC 现在拥有 7,370 股该医疗产品制造商的股票，价值 834,000 美元，此前在上个季度额外购买了 88 股。Wedge Capital Management L L P NC 在第三季度将其在雅培的持股增加了 2.9%。Wedge Capital Management L L P NC 现在拥有 3,153 股该医疗产品制造商的股票，价值 359,000 美元，此前在此期间额外购买了 89 股。最后，硅谷资本合伙公司在第三季度将其在雅培的持股增加了 8.7%。硅谷资本合伙公司现在拥有 1,108 股该医疗产品制造商的股票，价值 126,000 美元，此前在此期间额外购买了 89 股。目前 75.18% 的股票由机构投资者和对冲基金持有。</p>
<h2>内部买卖</h2>
<p>在其他消息中，执行副总裁 Daniel Gesua Sive Salvadori 于 1 月 30 日星期四出售了 23,771 股雅培股票。该股票以每股 128.50 美元的平均价格出售，总交易额为 3,054,573.50 美元。交易后，该执行副总裁现在直接持有 125,697 股公司股票，价值约为 16,152,064.50 美元。这笔交易代表其持仓减少了 15.90%。该出售在向证券交易委员会提交的文件中披露，可以通过此链接访问。公司内部人士持有公司股票的 1.10%。</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>这些是值得长期投资的顶级医疗股票</li>
</ul>
<p>最近，一些分析师对 ABT 股票发表了看法。Piper Sandler 将雅培股票的目标价从 131.00 美元上调至 133.00 美元，并在 10 月 17 日的研究报告中给予该股票 “超配” 评级。StockNews.com 在周三的研究报告中将雅培的评级从 “强力买入” 下调至 “买入”。巴克莱在 1 月 27 日的报告中重申了 “超配” 评级，并将雅培股票的目标价上调至 158.00 美元（之前为 149.00 美元）。瑞穗证券在 10 月 17 日的研究报告中将雅培股票的目标价从 115.00 美元上调至 130.00 美元，并给予公司 “中性” 评级。最后，Stifel Nicolaus 在 1 月 23 日的研究报告中将雅培股票的目标价从 130.00 美元上调至 135.00 美元，并给予公司 “买入” 评级。四位投资分析师对该股票给予持有评级，十四位给予买入评级，一位给予强力买入评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，平均目标价为 133.06 美元。</p>
<p><strong>查看我们关于 ABT 的最新报告</strong></p>
<h2>雅培股票表现</h2>
<ul>
<li>MarketBeat 周回顾 – 10/14 - 10/18</li>
</ul>
<p>ABT 股票在周五开盘价为 131.83 美元。该公司的市值为 2286.6 亿美元，市盈率为 17.23，市盈增长比率为 2.39，贝塔值为 0.75。该股票的 50 日简单移动平均为 118.34 美元，200 日简单移动平均为 115.71 美元。该公司的流动比率为 1.60，速动比率为 1.14，债务与股本比率为 0.32。雅培的 12 个月低点为 99.71 美元，12 个月高点为 132.50 美元。</p>
<p>雅培（NYSE:ABT - 获取免费报告）最近于 1 月 22 日星期三发布了季度财报。该医疗产品制造商报告的每股收益（EPS）为 1.34 美元，符合分析师一致预期的 1.34 美元。雅培的股本回报率为 20.74%，净利润率为 31.95%。该公司在本季度的收入为 109.7 亿美元，而分析师预期为 110.3 亿美元。在去年同期，该公司发布的每股收益为 1.19 美元。该公司的季度收入较去年同期增长了 7.2%。整体来看，股票研究分析师预测雅培在当前年度的每股收益将达到 5.14 美元。</p>
<h2>雅培增加股息</h2>
<p>该公司最近还宣布了一项季度股息，将于 2 月 14 日星期五支付。1 月 15 日星期三的股东将获得每股 0.59 美元的股息。这相当于年化股息为 2.36 美元，股息收益率为 1.79%。这比雅培之前的季度股息 0.55 美元有所增加。除息日期为 1 月 15 日星期三。雅培的股息支付比率（DPR）为 30.85%。</p>
<h2>雅培公司简介</h2>
<p>（免费报告）</p>
<p>雅培及其子公司在全球范围内发现、开发、制造和销售医疗保健产品。它分为四个业务板块：成熟药品、诊断产品、营养产品和医疗器械。该公司提供用于治疗胰腺外分泌功能不全、肠易激综合症或胆道痉挛、肝内胆汁淤积或抑郁症状、妇科疾病、激素替代疗法、血脂异常、高血压、甲状腺功能减退、梅尼埃病和前庭性眩晕、疼痛、发热、炎症和偏头痛的仿制药，以及提供抗感染药物克拉霉素、流感疫苗和调节结肠生理节律的产品。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票超过雅培</li>
<li>什么是成长股及其投资</li>
<li>Upstart 的上升趋势刚刚开始：是时候加仓了</li>
<li>如何投资 FAANG 股票</li>
<li>Archer Aviation 获得黑石投资——ACHR 的下一步是什么？</li>
<li>什么是澳大利亚证券交易所（ASX）</li>
<li>巴菲特增持西方石油——坚持他的投资策略</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 吗？</h2>
<p>在你进行下一笔交易之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。</p>
<p>我们的团队已识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐在更广泛的市场注意到之前购买……而且没有大名鼎鼎的股票在名单上。</p>
<p>他们认为这五只股票是投资者现在购买的五家最佳公司……</p>
<p>查看这五只股票</p>
<h2>你现在应该投资$1,000 在雅培吗？</h2>
<p>在你考虑雅培之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐在更广泛的市场注意到之前购买……而雅培不在名单上。</p>
<p>虽然雅培目前在分析师中获得了 “适度买入” 的评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

雅培

<p>资产管理一号有限公司在第四季度将其在雅培（NYSE:ABT）的持股增加了 8.4%，目前持有 781,611 股，价值为 8988 万美元。其他机构投资者也调整了他们的持仓。执行副总裁 Daniel Gesua Sive Salvadori 出售了 23,771 股，减少了 15.90% 的持股比例。分析师对 ABT 的评级不一，平均目标价为 133.06 美元。该股票开盘价为 131.83 美元，市值为 2286.6 亿美元，市盈率为 17.23</p>

<p>Asset Management One Co. Ltd. grew its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 8.4% in the 4th quarter, according to its most recent filing with the Securities &amp; Exchange Commission. The firm owned 781,611 shares of the healthcare product maker's stock after buying an additional 60,871 shares during the period. Asset Management One Co. Ltd.'s holdings in Abbott Laboratories were worth $89,877,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>资产管理一号有限公司在最近向证券交易委员会提交的文件中表示，在第四季度其在雅培（NYSE:ABT - 免费报告）股票中的持股增加了 8.4%。该公司在此期间额外购买了 60,871 股后，持有 781,611 股该医疗产品制造商的股票。根据其最近的 SEC 文件，资产管理一号有限公司在雅培的持股价值为 89,877,000 美元。</p>
</div><p>Get <strong>Abbott Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>雅培</strong> 的提醒：</p>
</div><ul>
<li>Abbott Laboratories Will Outperform Healthcare Stocks in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>雅培将在 2025 年表现优于医疗股票</li>
</ul>
</div><p>Other institutional investors and hedge funds have also made changes to their positions in the company. Insight Folios Inc increased its stake in Abbott Laboratories by 3.3% during the third quarter. Insight Folios Inc now owns 2,691 shares of the healthcare product maker's stock worth $307,000 after acquiring an additional 87 shares during the last quarter. Sfmg LLC raised its holdings in Abbott Laboratories by 1.9% in the third quarter. Sfmg LLC now owns 4,622 shares of the healthcare product maker's stock valued at $527,000 after buying an additional 88 shares during the period. River Street Advisors LLC lifted its position in Abbott Laboratories by 1.2% during the fourth quarter. River Street Advisors LLC now owns 7,370 shares of the healthcare product maker's stock valued at $834,000 after buying an additional 88 shares in the last quarter. Wedge Capital Management L L P NC grew its stake in Abbott Laboratories by 2.9% during the third quarter. Wedge Capital Management L L P NC now owns 3,153 shares of the healthcare product maker's stock worth $359,000 after buying an additional 89 shares during the period. Finally, Silicon Valley Capital Partners raised its stake in shares of Abbott Laboratories by 8.7% in the 3rd quarter. Silicon Valley Capital Partners now owns 1,108 shares of the healthcare product maker's stock valued at $126,000 after acquiring an additional 89 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他机构投资者和对冲基金也对该公司的持仓进行了调整。Insight Folios Inc 在第三季度将其在雅培的持股增加了 3.3%。Insight Folios Inc 现在拥有 2,691 股该医疗产品制造商的股票，价值 307,000 美元，此前在上个季度额外购买了 87 股。Sfmg LLC 在第三季度将其在雅培的持股增加了 1.9%。Sfmg LLC 现在拥有 4,622 股该医疗产品制造商的股票，价值 527,000 美元，此前在此期间额外购买了 88 股。River Street Advisors LLC 在第四季度将其在雅培的持股增加了 1.2%。River Street Advisors LLC 现在拥有 7,370 股该医疗产品制造商的股票，价值 834,000 美元，此前在上个季度额外购买了 88 股。Wedge Capital Management L L P NC 在第三季度将其在雅培的持股增加了 2.9%。Wedge Capital Management L L P NC 现在拥有 3,153 股该医疗产品制造商的股票，价值 359,000 美元，此前在此期间额外购买了 89 股。最后，硅谷资本合伙公司在第三季度将其在雅培的持股增加了 8.7%。硅谷资本合伙公司现在拥有 1,108 股该医疗产品制造商的股票，价值 126,000 美元，此前在此期间额外购买了 89 股。目前 75.18% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In other news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of Abbott Laboratories stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $128.50, for a total transaction of $3,054,573.50. Following the transaction, the executive vice president now directly owns 125,697 shares in the company, valued at approximately $16,152,064.50. This trade represents a 15.90 % decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. Corporate insiders own 1.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，执行副总裁 Daniel Gesua Sive Salvadori 于 1 月 30 日星期四出售了 23,771 股雅培股票。该股票以每股 128.50 美元的平均价格出售，总交易额为 3,054,573.50 美元。交易后，该执行副总裁现在直接持有 125,697 股公司股票，价值约为 16,152,064.50 美元。这笔交易代表其持仓减少了 15.90%。该出售在向证券交易委员会提交的文件中披露，可以通过此链接访问。公司内部人士持有公司股票的 1.10%。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><ul>
<li>These Are The Top Health Stocks to Own for Buy-and-Hold Investing</li>
</ul>
<div class="lb-trans"><ul>
<li>这些是值得长期投资的顶级医疗股票</li>
</ul>
</div><p>A number of analysts recently weighed in on ABT shares. Piper Sandler upped their price target on shares of Abbott Laboratories from $131.00 to $133.00 and gave the stock an &#34;overweight&#34; rating in a research report on Thursday, October 17th. StockNews.com lowered Abbott Laboratories from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research note on Wednesday. Barclays restated an &#34;overweight&#34; rating and issued a $158.00 price target (up previously from $149.00) on shares of Abbott Laboratories in a report on Monday, January 27th. Mizuho lifted their price objective on shares of Abbott Laboratories from $115.00 to $130.00 and gave the company a &#34;neutral&#34; rating in a research note on Thursday, October 17th. Finally, Stifel Nicolaus upped their target price on shares of Abbott Laboratories from $130.00 to $135.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday, January 23rd. Four investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $133.06.</p>
<div class="lb-trans"><p>最近，一些分析师对 ABT 股票发表了看法。Piper Sandler 将雅培股票的目标价从 131.00 美元上调至 133.00 美元，并在 10 月 17 日的研究报告中给予该股票 “超配” 评级。StockNews.com 在周三的研究报告中将雅培的评级从 “强力买入” 下调至 “买入”。巴克莱在 1 月 27 日的报告中重申了 “超配” 评级，并将雅培股票的目标价上调至 158.00 美元（之前为 149.00 美元）。瑞穗证券在 10 月 17 日的研究报告中将雅培股票的目标价从 115.00 美元上调至 130.00 美元，并给予公司 “中性” 评级。最后，Stifel Nicolaus 在 1 月 23 日的研究报告中将雅培股票的目标价从 130.00 美元上调至 135.00 美元，并给予公司 “买入” 评级。四位投资分析师对该股票给予持有评级，十四位给予买入评级，一位给予强力买入评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，平均目标价为 133.06 美元。</p>
</div><p><strong>View Our Latest Report on ABT</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 ABT 的最新报告</strong></p>
</div><h2>Abbott Laboratories Stock Performance</h2>
<div class="lb-trans"><h2>雅培股票表现</h2>
</div><ul>
<li>MarketBeat Week in Review – 10/14 - 10/18</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 10/14 - 10/18</li>
</ul>
</div><p>ABT stock opened at $131.83 on Friday. The firm has a market cap of $228.66 billion, a P/E ratio of 17.23, a P/E/G ratio of 2.39 and a beta of 0.75. The stock's 50 day simple moving average is $118.34 and its 200 day simple moving average is $115.71. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. Abbott Laboratories has a 12-month low of $99.71 and a 12-month high of $132.50.</p>
<div class="lb-trans"><p>ABT 股票在周五开盘价为 131.83 美元。该公司的市值为 2286.6 亿美元，市盈率为 17.23，市盈增长比率为 2.39，贝塔值为 0.75。该股票的 50 日简单移动平均为 118.34 美元，200 日简单移动平均为 115.71 美元。该公司的流动比率为 1.60，速动比率为 1.14，债务与股本比率为 0.32。雅培的 12 个月低点为 99.71 美元，12 个月高点为 132.50 美元。</p>
</div><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.34. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The business had revenue of $10.97 billion during the quarter, compared to analyst estimates of $11.03 billion. During the same quarter in the previous year, the firm posted $1.19 EPS. The business's revenue for the quarter was up 7.2% compared to the same quarter last year. As a group, equities research analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 获取免费报告）最近于 1 月 22 日星期三发布了季度财报。该医疗产品制造商报告的每股收益（EPS）为 1.34 美元，符合分析师一致预期的 1.34 美元。雅培的股本回报率为 20.74%，净利润率为 31.95%。该公司在本季度的收入为 109.7 亿美元，而分析师预期为 110.3 亿美元。在去年同期，该公司发布的每股收益为 1.19 美元。该公司的季度收入较去年同期增长了 7.2%。整体来看，股票研究分析师预测雅培在当前年度的每股收益将达到 5.14 美元。</p>
</div><h2>Abbott Laboratories Increases Dividend</h2>
<div class="lb-trans"><h2>雅培增加股息</h2>
</div><p>The firm also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be issued a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.79%. This is a positive change from Abbott Laboratories's previous quarterly dividend of $0.55. The ex-dividend date is Wednesday, January 15th. Abbott Laboratories's dividend payout ratio (DPR) is 30.85%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度股息，将于 2 月 14 日星期五支付。1 月 15 日星期三的股东将获得每股 0.59 美元的股息。这相当于年化股息为 2.36 美元，股息收益率为 1.79%。这比雅培之前的季度股息 0.55 美元有所增加。除息日期为 1 月 15 日星期三。雅培的股息支付比率（DPR）为 30.85%。</p>
</div><h2>Abbott Laboratories Profile</h2>
<div class="lb-trans"><h2>雅培公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.</p>
<div class="lb-trans"><p>雅培及其子公司在全球范围内发现、开发、制造和销售医疗保健产品。它分为四个业务板块：成熟药品、诊断产品、营养产品和医疗器械。该公司提供用于治疗胰腺外分泌功能不全、肠易激综合症或胆道痉挛、肝内胆汁淤积或抑郁症状、妇科疾病、激素替代疗法、血脂异常、高血压、甲状腺功能减退、梅尼埃病和前庭性眩晕、疼痛、发热、炎症和偏头痛的仿制药，以及提供抗感染药物克拉霉素、流感疫苗和调节结肠生理节律的产品。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Abbott Laboratories</li>
<li>What Are Growth Stocks and Investing in Them</li>
<li>Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up</li>
<li>How to Invest in the FAANG Stocks</li>
<li>Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?</li>
<li>What is the Australian Securities Exchange (ASX)</li>
<li>Buffett Buys More Occidental Petroleum—Sticking to His Playbook</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过雅培</li>
<li>什么是成长股及其投资</li>
<li>Upstart 的上升趋势刚刚开始：是时候加仓了</li>
<li>如何投资 FAANG 股票</li>
<li>Archer Aviation 获得黑石投资——ACHR 的下一步是什么？</li>
<li>什么是澳大利亚证券交易所（ASX）</li>
<li>巴菲特增持西方石油——坚持他的投资策略</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Where Should You Invest $1,000 Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 吗？</h2>
</div><p>Before you make your next trade, you'll want to hear this.</p>
<div class="lb-trans"><p>在你进行下一笔交易之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。</p>
</div><p>Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.</p>
<div class="lb-trans"><p>我们的团队已识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐在更广泛的市场注意到之前购买……而且没有大名鼎鼎的股票在名单上。</p>
</div><p>They believe these five stocks are the five best companies for investors to buy now...</p>
<div class="lb-trans"><p>他们认为这五只股票是投资者现在购买的五家最佳公司……</p>
</div><p>See The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在雅培吗？</h2>
</div><p>Before you consider Abbott Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑雅培之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐在更广泛的市场注意到之前购买……而雅培不在名单上。</p>
</div><p>While Abbott Laboratories currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然雅培目前在分析师中获得了 “适度买入” 的评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

资产管理一号有限公司购买了雅培（纽约证券交易所代码：ABT）的股票